Literature DB >> 30548257

Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).

Kamel Laribi1, Stéphanie Poulain2, Lise Willems3, Fatiha Merabet4, Ronan Le Calloch5, Jean R Eveillard6, Charles Herbaux7, Damien Roos-Weil8, Driss Chaoui9, Xavier Roussel9, Sabine Tricot10, Jehan Dupuis11, Caroline Dartigeas12, Benoit Bareau13, Marie C Bene14, Alix Baugier de Materre15, Véronique Leblond16.   

Abstract

Entities:  

Keywords:  Waldenström macroglobulinaemia; bendamustine; rituximab

Mesh：

Substances：

Year:  2018        PMID： 30548257     DOI： 10.1111/bjh.15718

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.

Authors:  Saurabh Zanwar; Jithma Prasad Abeykoon; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

Review 2.  Management of Waldenström macroglobulinemia in 2020.

Authors:  Jorge J Castillo; Steven P Treon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 3.  Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual.

Authors:  Morie A Gertz
Journal:  J Clin Oncol       Date:  2022-06-14       Impact factor: 50.717

Review 4.  The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.

Authors:  Abdullah Mohammad Khan
Journal:  J Pers Med       Date:  2022-04-22

Review 5.  Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.

Authors:  Saurabh Zanwar; Jithma P Abeykoon
Journal:  Ther Adv Hematol       Date:  2022-04-29

Review 6.  Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.

Authors:  Steven P Treon; Lian Xu; Maria Luisa Guerrera; Cristina Jimenez; Zachary R Hunter; Xia Liu; Maria Demos; Joshua Gustine; Gloria Chan; Manit Munshi; Nicholas Tsakmaklis; Jiaji G Chen; Amanda Kofides; Romanos Sklavenitis-Pistofidis; Mark Bustoros; Andrew Keezer; Kirsten Meid; Christopher J Patterson; Antonio Sacco; Aldo Roccaro; Andrew R Branagan; Guang Yang; Irene M Ghobrial; Jorge J Castillo
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

7.  Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.

Authors:  Meletios Dimopoulos; Ramon Garcia Sanz; Hui-Peng Lee; Marek Trneny; Marzia Varettoni; Stephen Opat; Shirley D'Sa; Roger G Owen; Gavin Cull; Stephen Mulligan; Jaroslaw Czyz; Jorge J Castillo; Marina Motta; Tanya Siddiqi; Mercedes Gironella Mesa; Miquel Granell Gorrochategui; Dipti Talaulikar; Pier Luigi Zinzani; Elham Askari; Sebastian Grosicki; Albert Oriol; Simon Rule; Janusz Kloczko; Alessandra Tedeschi; Christian Buske; Veronique Leblond; Judith Trotman; Wai Y Chan; Jan Michel; Jingjing Schneider; Ziwen Tan; Aileen Cohen; Jane Huang; Constantine S Tam
Journal:  Blood Adv       Date:  2020-12-08

8.  Waldenström's macroglobulinemia front line treatment.

Authors:  Alessandra Tedeschi; Anna Maria Frustaci
Journal:  Hemasphere       Date:  2019-06-30

9.  Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?

Authors:  Julien Labreuche; Deborah Assouan; Eric Durot; Cecile Tomowiak; Damien Roos-Weil; Elise Toussaint; Fontanet Bijou; Richard Lemal; Annie Brion; Kamel Laribi; Loic Ysebaert; Alain Duhamel; Pierre Morel
Journal:  Hematol Oncol       Date:  2022-05-01       Impact factor: 4.850

Review 10.  Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies.

Authors:  Ava J Boutilier; Lina Huang; Sherine F Elsawa
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.